Skye Bioscience R&D Spending Growth & History (SKYE)

Skye Bioscience's r&d spending was $42.4M for fiscal 2025.

View full Skye Bioscience company overview

Skye Bioscience annual r&d spending history

Skye Bioscience annual r&d spending

Fiscal yearPeriod endedR&D spendingChangeGrowth
20252025-12-31$42.4M$23.7M+126.51%
20242024-12-31$18.7M$12.9M+221.36%
20232023-12-31$5.8M−$192,344−3.20%
20222022-12-31$6.0M$3.1M+105.08%
20212021-12-31$2.9M$987,026+50.76%
20202020-12-31$1.9M−$293,545−13.12%
20192019-12-31$2.2M$1.9M+578.24%
20182018-12-31$329,966$18,664+6.00%
20172017-12-31$311,302−$627,738−66.85%
20162016-12-31$939,040$362,947+63.00%
20152015-12-31$576,093$348,593+153.23%
20142014-12-31$227,500

Skye Bioscience r&d spending trends

Over the last five fiscal years, Skye Bioscience's r&d spending increased from $1.9M to $42.4M, a change of $40.4M. The latest reported quarter, Q2 2026, shows $3.9M.

About the metric

What research and development spending means

Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.

Calculation and source

SEC-reported R&D expense

TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Skye Bioscience source filings ↗

Community posts

It’s quiet here.

No posts about SKYE yet. Start the conversation.

Write the first post